Evidence map›Paper›PMID 40993821›Full record

ArticleTrials2025

Caffeine to improve neurodevelopmental outcomes in infants born late preterm (The Latte Trial): study protocol for a randomised controlled trial.

Jane M Canning, Christopher J D McKinlay, David G McNamara, Liza K Edmonds, Jenny A Rogers, Braden Te Ao, Alana Cavadino, Elizabeth A Oliphant, Jane M Alsweiler

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jane M CanningDepartment of Paediatrics: Child and Youth Health, University of Auckland and Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand. jcan015@aucklanduni.ac.nz.ORCID http://orcid.org/0000-0002-8155-9564
Christopher J D McKinlayDepartment of Paediatrics: Child and Youth Health, University of Auckland and Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand.
David G McNamaraStarship Hospital, Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand.
Liza K EdmondsTe Tātai Hauora o Hine Te Herenga Waka Victoria University of Wellington, Wellington, New Zealand.
Jenny A RogersLiggins Institute, University of Auckland, Auckland, New Zealand.
Braden Te AoSchool of Population Health, University of Auckland, Auckland, New Zealand.
Alana CavadinoSchool of Population Health, University of Auckland, Auckland, New Zealand.
Elizabeth A OliphantSchool of Pharmacy, University of Auckland, Auckland, New Zealand.
Jane M AlsweilerDepartment of Paediatrics: Child and Youth Health, University of Auckland and Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand.

Funding

Health Research Council of New Zealand (NZ) 22/305
6 · The paper itself

Abstract

backgroundLate preterm infants (34

methodsThis phase III multi-centre, parallel two-arm, double-blind, placebo-controlled randomised superiority trial will randomise 478 late preterm infants or twin pairs to receive caffeine citrate (loading dose 40 mg.kg DISCUSSION: Of early developmental domains, cognition is the most predictive of later neurodevelopmental outcome and intelligence quotient. Prioritisation of the Indigenous population within trials is important. If prophylactic caffeine citrate is found to improve neurodevelopment in late preterm infants, this could have a significant impact on the long-term quality of life and health and wellbeing of this large population of infants.

trial registrationANZCTR ACTRN12622001344785. Registered on 19 October 2022.

Indexed as

CaffeineCentral Nervous System StimulantsChild DevelopmentCitratesInfant, PrematureAge FactorsCognitionDouble-Blind MethodEquivalence Trials as TopicFemaleGestational AgeHumansInfantInfant, NewbornMaleMulticenter Studies as TopicCaffeinecaffeine citrateCentral Nervous System StimulantsCitratesCaffeineCognitionIndigenousInfantIntermittent hypoxaemiaLate pretermNeonatalNeurodevelopmental outcome

Identifiers

PMID40993821
PMCPMC12462362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.